Cargando…
Universal response in the RKO colon cancer cell line to distinct antimitotic therapies
Both classic and newer antimitotics commonly induce a prolonged mitotic arrest in cell culture. During arrest, cells predominantly undergo one of two fates: cell death by apoptosis, or mitotic slippage and survival. To refine this binary description, a quantitative understanding of these cell respon...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997697/ https://www.ncbi.nlm.nih.gov/pubmed/29895957 http://dx.doi.org/10.1038/s41598-018-27267-7 |
_version_ | 1783331089712939008 |
---|---|
author | Lorz, Alexander Botesteanu, Dana-Adriana Levy, Doron |
author_facet | Lorz, Alexander Botesteanu, Dana-Adriana Levy, Doron |
author_sort | Lorz, Alexander |
collection | PubMed |
description | Both classic and newer antimitotics commonly induce a prolonged mitotic arrest in cell culture. During arrest, cells predominantly undergo one of two fates: cell death by apoptosis, or mitotic slippage and survival. To refine this binary description, a quantitative understanding of these cell responses is needed. Herein, we propose a quantitative description of the kinetics of colon carcinoma RKO cell fates in response to different antimitotics, using data from the single cell experiments of Gascoigne and Taylor (2008). The mathematical model is calibrated using the in vitro experiments of Gascoigne and Taylor (2008). We show that the time-dependent probability of cell death or slippage is universally identical for monastrol, nocodazole and two different doses of AZ138, but significantly different for taxol. Death and slippage responses across drugs can be characterized by Gamma distributions. We demonstrate numerically that these rates increase with prolonged mitotic arrest. Our model demonstrates that RKO cells exhibit a triphasic response - first, remain in mitosis, then undergo fast and slow transition, respectively- dependent on the length of mitotic arrest and irrespective of cell fate, drug type or dose. |
format | Online Article Text |
id | pubmed-5997697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-59976972018-06-21 Universal response in the RKO colon cancer cell line to distinct antimitotic therapies Lorz, Alexander Botesteanu, Dana-Adriana Levy, Doron Sci Rep Article Both classic and newer antimitotics commonly induce a prolonged mitotic arrest in cell culture. During arrest, cells predominantly undergo one of two fates: cell death by apoptosis, or mitotic slippage and survival. To refine this binary description, a quantitative understanding of these cell responses is needed. Herein, we propose a quantitative description of the kinetics of colon carcinoma RKO cell fates in response to different antimitotics, using data from the single cell experiments of Gascoigne and Taylor (2008). The mathematical model is calibrated using the in vitro experiments of Gascoigne and Taylor (2008). We show that the time-dependent probability of cell death or slippage is universally identical for monastrol, nocodazole and two different doses of AZ138, but significantly different for taxol. Death and slippage responses across drugs can be characterized by Gamma distributions. We demonstrate numerically that these rates increase with prolonged mitotic arrest. Our model demonstrates that RKO cells exhibit a triphasic response - first, remain in mitosis, then undergo fast and slow transition, respectively- dependent on the length of mitotic arrest and irrespective of cell fate, drug type or dose. Nature Publishing Group UK 2018-06-12 /pmc/articles/PMC5997697/ /pubmed/29895957 http://dx.doi.org/10.1038/s41598-018-27267-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Lorz, Alexander Botesteanu, Dana-Adriana Levy, Doron Universal response in the RKO colon cancer cell line to distinct antimitotic therapies |
title | Universal response in the RKO colon cancer cell line to distinct antimitotic therapies |
title_full | Universal response in the RKO colon cancer cell line to distinct antimitotic therapies |
title_fullStr | Universal response in the RKO colon cancer cell line to distinct antimitotic therapies |
title_full_unstemmed | Universal response in the RKO colon cancer cell line to distinct antimitotic therapies |
title_short | Universal response in the RKO colon cancer cell line to distinct antimitotic therapies |
title_sort | universal response in the rko colon cancer cell line to distinct antimitotic therapies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997697/ https://www.ncbi.nlm.nih.gov/pubmed/29895957 http://dx.doi.org/10.1038/s41598-018-27267-7 |
work_keys_str_mv | AT lorzalexander universalresponseintherkocoloncancercelllinetodistinctantimitotictherapies AT botesteanudanaadriana universalresponseintherkocoloncancercelllinetodistinctantimitotictherapies AT levydoron universalresponseintherkocoloncancercelllinetodistinctantimitotictherapies |